Mitzi Williams, MD
Neurology · Smyrna, GANPI 1356461248
Payments from drug & device makers
Across 1,521 payments — averaging $977.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$395K
- Biogen$366K
- Genentech USA, Inc.$187K
- Sanofi$126K
- Genentech, Inc.$101K
- Novartis$83K
- plus $229K from 30 others
Across 43 payments — averaging $1279.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$34K
- Novartis$17K
- Sanofi$3K
- Novartis Pharma AG$1K
What the payments were for
- Consulting fees$431,00830%
- Speaking & faculty fees$807,63456%
- Grants$4,0000%
- Travel & lodging$138,98610%
- Food & beverage$32,0812%
- Education$13,8861%
- Charitable contribution$5,0000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 477 | $394,703 |
| Biogen | 342 | $366,468 |
| Genentech USA, Inc. | 144 | $187,265 |
| Sanofi | 59 | $125,853 |
| Genentech, Inc. | 65 | $100,629 |
| Novartis | 92 | $82,830 |
| E.r. Squibb & Sons, L.L.C. | 19 | $44,162 |
| Merck Kgaa | 18 | $38,574 |
| TG Therapeutics, Inc. | 51 | $32,376 |
| F. Hoffmann-la Roche AG | 11 | $26,366 |
| Bristol Myers Squibb | 46 | $20,618 |
| Amgen(2 entities) | 83 | $18,742 |
| Teva Pharmaceuticals USA, Inc. | 7 | $15,178 |
| AstraZeneca | 27 | $13,365 |
| Johnson & Johnson(2 entities) | 31 | $12,222 |
| Novartis Pharma AG | 1 | $3,458 |
| Janssen Scientific Affairs, LLC | 1 | $1,320 |
| Cycle Pharmaceuticals Inc | 2 | $1,183 |
| AbbVie | 11 | $251 |
| Mallinckrodt Hospital Products Inc. | 6 | $143 |
| Intrafusion GP, LLC | 2 | $111 |
| ANI Pharmaceuticals, Inc. | 4 | $92 |
| Pfizer | 3 | $73 |
| Lundbeck LLC | 2 | $57 |
| Acorda Therapeutics, Inc | 3 | $57 |
| Argenx US, Inc. | 2 | $55 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Mylan Specialty L.p. | 1 | $36 |
| Aucta Pharmaceuticals, Inc. | 2 | $34 |
| UCB, Inc. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Greenwich Biosciences, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,486,422 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 19 | $175,981 |
| Dimethyl Fumarate | 25 | $34,576 |
| Glatiramer Acetate | 13 | $18,387 |
| Teriflunomide | 23 | $964 |
| Baclofen | 50 | $560 |
| Tizanidine Hcl | 31 | $310 |
| Gabapentin | 28 | $244 |
| ClopidogrelClopidogrel Bisulfate | 15 | $173 |
| Levetiracetam | 11 | $117 |
| Amitriptyline Hcl | 11 | $95 |
Paid to pharmacies, not to this prescriber.
Other neurology in Smyrna
- Jakai McEwenSmyrna$56K
- Jonathan LissColumbus$25M
- Marshall NashDecatur$13.6M
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Sandeep VaidLawrenceville$4.2M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
- Dennis LaceyAtlanta$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.